Risk Assessments Of New Drug Elemental Impurities Get Mixed Reviews From Regulators
Executive Summary
ICH Q3D went into effect in June 2016 for new drugs, but so far doesn't seem to have completely resolved worries about the presence of elemental impurities in drug products.
You may also be interested in...
Regulators Find Room For ICH Q3D Metal Impurity Risk Assessments To Improve
The pharmaceutical industry is doing a better job of conducting the risk assessments called for in the ICH Q3D elemental impurity limits guideline, and regulators are not rejecting applications because of poor quality assessments, yet regulators say there is still room for improvement.
FDA Warns Lymol To Assess Talc Lead Risk Per ICH Q3D; Puts Others On Notice
A warning letter to firm with legacy talc drug product puts pharmaceutical industry on notice: the US FDA expects applicants to meet requirements agency imposes post-approval for matters like elemental impurities compliance.
Manufacturing Regulatory Updates In Brief: Elemental Impurities, Class 3 Biowaivers, FDA Salt Policy
Manufacturing US regulatory updates for December 2017: Elemental impurities requirements begin Jan. 1, final guidance confirms BCS Class 3 biowaivers option, and FDA MAPP implements USP salt policy.